Dr. Kelly L. Vallance
Claim this profileCook Children's Medical Center
Expert in Tumors
Expert in Cancer
20 reported clinical trials
35 drugs studied
About Kelly L. Vallance
Education:
- Earned a Medical degree (MD).
Experience:
- Serves as the primary investigator for oncology research studies at Cook Children's Medical Center.
- Specializes in pediatric oncology, focusing on Wilms tumors, a type of kidney cancer in children.
- Actively engaged in advancing treatments for childhood cancers through clinical research.
Area of expertise
1Tumors
Global LeaderStage I
Stage II
Stage IV
2Cancer
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Kelly L. Vallance is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Kelly L. Vallance
Clinical Trial Related7 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Kelly L. Vallance has experience with
- Cyclophosphamide
- Carboplatin
- Etoposide
- Erdafitinib
- Olaparib
- Palbociclib
Breakdown of trials Kelly L. Vallance has run
Tumors
Cancer
Rhabdoid Tumor
Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kelly L. Vallance specialize in?
Kelly L. Vallance focuses on Tumors and Cancer. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage II.
Is Kelly L. Vallance currently recruiting for clinical trials?
Yes, Kelly L. Vallance is currently recruiting for 6 clinical trials in Fort Worth Texas. If you're interested in participating, you should apply.
Are there any treatments that Kelly L. Vallance has studied deeply?
Yes, Kelly L. Vallance has studied treatments such as Cyclophosphamide, Carboplatin, Etoposide.
What is the best way to schedule an appointment with Kelly L. Vallance?
Apply for one of the trials that Kelly L. Vallance is conducting.
What is the office address of Kelly L. Vallance?
The office of Kelly L. Vallance is located at: Cook Children's Medical Center, Fort Worth, Texas 76104 United States. This is the address for their practice at the Cook Children's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.